Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.280 +0.010 (+0.79%)
Streaming Delayed Price Updated: 2:44 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 267,949
Open 1.300
Bid (Size) 1.280 (1,000)
Ask (Size) 1.290 (200)
Prev. Close 1.270
Today's Range 1.265 - 1.320
52wk Range 1.090 - 11.64
Shares Outstanding 17,703,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire

Performance

YTD
-16.9%
-16.9%
1 Month
-2.3%
-2.3%
3 Month
-17.9%
-17.9%
6 Month
-34.7%
-34.7%
1 Year
-82.5%
-82.5%

More News

Read More
News headline image
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
From INmune Bio, Inc.
Via GlobeNewswire
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? ↗
Via Stocktwits
News headline image
Earnings Scheduled For October 30, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INMUNE BIO INC (NASDAQ:INMB) Reports Narrower-Than-Expected Q3 2025 Loss ↗
Via Chartmill
News headline image
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio (INMB) Q2 Loss Widens 110% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
From INmune Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is INmune Bio Inc. - Common stock publicly traded?
Yes, INmune Bio Inc. - Common stock is publicly traded.
What exchange does INmune Bio Inc. - Common stock trade on?
INmune Bio Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for INmune Bio Inc. - Common stock?
The ticker symbol for INmune Bio Inc. - Common stock is INMB on the Nasdaq Stock Market
What is the current price of INmune Bio Inc. - Common stock?
The current price of INmune Bio Inc. - Common stock is 1.280
When was INmune Bio Inc. - Common stock last traded?
The last trade of INmune Bio Inc. - Common stock was at 04/08/26 02:44 PM ET
What is the market capitalization of INmune Bio Inc. - Common stock?
The market capitalization of INmune Bio Inc. - Common stock is 22.66M
How many shares of INmune Bio Inc. - Common stock are outstanding?
INmune Bio Inc. - Common stock has 23M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.